Published in Prostate Cancer Prostatic Dis on March 18, 2014
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol (2014) 0.92
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. Adv Ther (2016) 0.78
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer (2016) 0.77
Prostate cancer: CYP17A1 inhibitor failure-lessons for future drug development. Nat Rev Urol (2015) 0.75
Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy. Oncol Lett (2016) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol (2009) 6.68
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2012) 6.49
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol (2010) 5.86
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol (2010) 4.64
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer (2004) 3.32
Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol (2011) 2.99
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol (2013) 2.57
Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res (2010) 2.39
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res (2011) 2.23
Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res (2007) 2.03
Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer. J Natl Cancer Inst (1999) 1.25
Serum testosterone assays--accuracy matters. J Clin Endocrinol Metab (2004) 1.19
Rapid glucocorticoid receptor-mediated inhibition of hypothalamic-pituitary-adrenal ultradian activity in healthy males. J Neurosci (2010) 1.10
From pathogenesis to prevention of castration resistant prostate cancer. Prostate (2010) 1.09
Interlaboratory comparison study of serum total testosterone [corrected] measurements performed by mass spectrometry methods. Steroids (2009) 1.00
A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2002) 0.98
CYP17 polymorphisms and prostate cancer outcomes. Prostate (2010) 0.95
Novel secondary hormonal therapy in advanced prostate cancer: an update. Curr Opin Urol (2009) 0.94
Association of a CYP17 polymorphism with overall survival in Caucasian patients with androgen-independent prostate cancer. Urology (2007) 0.91
The sensitivity of testosterone immunoassays and their role in monitoring antiandrogen therapy. Urol Oncol (2006) 0.77
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2013) 1.22
Is There A Relationship Between Patient-Reported Outcomes (Pros) And Clinical Outcomes In Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Post-Docetaxel? Value Health (2015) 0.75
Analysis of the Relationship Between Patient-Reported Outcomes (Pros) and Clinical Outcomes In Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients without Prior Chemotherapy. Value Health (2015) 0.75
Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post-hoc analysis of COU-AA-301 and COU-AA-302. Ann Oncol (2017) 0.75